|
1) Nagano N. Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther. 2006; 109: 339-65
|
|
|
|
2) Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005; 16: 1788-93
|
|
|
|
|
|
3) Hussein MR, Ali HO, Abdulwahed SR, et al. Calciphylaxis cutis: A case report and review of literature. Exp Mol Pathol. 2009; 86: 134-5
|
|
|
|
|
|
4) Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008; 19: 213-6
|
|
|
|
|
|
5) Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007; 116: 85-97
|
|
|
|
|
|
6) Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004; 66: 2293-9
|
|
|
|
|
|
7) Giachelli CM, Speer MY, Li X, et al. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005; 96: 717-22
|
|
|
|
|
|
8) Jono S, Nishizawa Y, Shioi A, et al. 1, 25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998; 98: 1302-6
|
|
|
|
|
|
9) Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003; 63: 1003-11
|
|
|
|
|
|
10) Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003; 107: 2181-4
|
|
|
|
|
|
11) Verberckmoes SC, Persy V, Behets GJ, et al. Uremia-related vascular calcification: more than apatite deposition. Kidney Int. 2007; 71: 298-303
|
|
|
|
|
|
12) Eanes ED, Termine JD, Posner AS. Amorphous calcium phosphate in skeletal tissues. Clin Orthop. 1967; 53; 223-35
|
|
|
|
|
|
13) Montel G, Bonel G, Heughebaert JC, et al. New concepts in the composition, crystallization and growth of the mineral component of calcified tissues. J Crystal Growth. 1981; 53: 74-99
|
|
|
|
|
|
14) Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000; 15: 218-23
|
|
|
|
|
|
15) Kawata T, Nagano N, Obi M, et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int. 2008; 74: 1270-7
|
|
|
|
|
|
16) Lopez I, Mendoza FJ, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int. 2008; 73: 300-7
|
|
|
|
|
|
17) Ivanovski O, Nikolov IG, Joki N, et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient apoE(-/-) mice. Atherosclerosis. 2009; 205: 55-62
|
|
|
|
|
|
18) Nakagawa K, Parekh N, Koleganova N, et al. Acute cardiovascular effects of the calcimimetic R-568 and its enantiomer S-568 in rats. Pediatr Nephrol. 2009; 24: 1385-9
|
|
|
|
|
|
19) Smajilovic S, Sheykhzade M, Holmegard HN, et al. Calcimimetic, AMG 073, induces relaxation on isolated rat aorta. Vascul Pharmacol. 2007; 47: 222-8
|
|
|
|
|
|
20) Bas A, Lopez I, Perez J, et al. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res. 2006; 21: 484-90
|
|
|
|
|
|
21) Lopez I, Mendoza FJ, Guerrero F, et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol. 2009; 296: F1376-85
|
|
|
|
|
|
22) Shuvy M, Abedat S, Beeri R, et al. Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. Cardiovasc Res. 2008; 79: 492-9
|
|
|
|
|
|
23) Velasco N, MacGregor MS, Innes A, et al. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy？ Nephrol Dial Transplant. 2006; 21: 1999-2004
|
|
|
|
|
|
24) Mohammed IA, Sekar V, Bubtana AJ, et al. Proximal calciphylaxis treated with calcimimetic ‘Cinacalcet'. Nephrol Dial Transplant. 2008; 23: 387-9
|
|
|
|
|
|
25) Regidor A. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. Clin Nephrol. 2009; 71: 207-13
|
|
|
|
|
|
26) Alam MU, Kirton JP, Wilkinson FL, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res. 2009; 81: 260-8
|
|
|
|
|
|
27) Molostvov G, James S, Fletcher S, et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol. 2007; 293: F946-55
|
|
|
|
|
|
28) Koleganova N, Piecha G, Ritz E, et al. Calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int. 2009; 75: 60-71
|
|
|
|
|
|
29) Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 68: 1793-800
|
|
|
|
|
|
30) Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007; 2: 898-905
|
|
|
|
|